LeMaitre Vascular (LMAT) director gains shares from PSU and dividend rights

Rhea-AI Filing Summary

LeMaitre Vascular director John James O'Connor reported equity awards and related conversions, not open-market trading. On February 26, 2026 he acquired 476 shares of common stock at $0.0000 per share as a grant or award, bringing his direct common stock holdings to 62,826 shares, then to 62,827 shares after a related derivative conversion.

He also exercised 1 dividend equivalent right and converted it into 1 share of common stock, and now holds 2.8963 dividend equivalent rights. Footnotes explain these transactions relate to a Performance Share Unit award granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remainder vesting in equal annual installments over the next two years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor John James

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		476(1)	A	$0	62,826	D
Common Stock	02/26/2026		M		1(2)	A	$0(2)	62,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(3)	02/26/2026		M			1(3)	(3)	(3)	Common Stock	1	$0	2.8963	D

Explanation of Responses:

1. These shares represent LMAT common stock acquired on February 26, 2026, upon settlement of a Performance Share Unit (PSU) award granted on December 6, 2024. The PSU award vested 1/3 upon determination of satisfaction of the performance condition (on 2/26/2026), and the balance vests in equal annual installments on the grant date anniversary over the next two years.

2. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

3. These dividend equivalent rights were released in connection with the vesting of a PSU award granted on December 6, 2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did LeMaitre Vascular (LMAT) director John James O'Connor report in this Form 4?

He reported acquiring equity through awards and related conversions, not open-market trades. On February 26, 2026 he received 476 shares of common stock and additional shares tied to a Performance Share Unit and dividend equivalent rights vesting.

How many LeMaitre Vascular (LMAT) shares did John James O'Connor acquire?

He acquired 476 shares of common stock as a grant and 1 additional share through a derivative conversion. After these transactions, his direct common stock holdings increased to 62,827 shares, according to the reported post-transaction ownership figures.

What are the dividend equivalent rights reported by LeMaitre Vascular (LMAT) director O'Connor?

Dividend equivalent rights are instruments economically equivalent to common stock. O'Connor exercised 1 right into 1 common share and now holds 2.8963 rights. Footnotes state each right is the economic equivalent of one share of LeMaitre Vascular common stock.

How is the LeMaitre Vascular (LMAT) Performance Share Unit award structured for O'Connor?

The Performance Share Unit award was granted on December 6, 2024. It vested one-third on February 26, 2026 upon determination that its performance condition was met, with the remaining two-thirds vesting in equal annual installments on the grant date anniversary over the next two years.

Were John James O'Connor's LeMaitre Vascular (LMAT) transactions open-market purchases or sales?

They were not open-market purchases or sales. The filing describes them as a grant or award acquisition and derivative exercises or conversions tied to a Performance Share Unit award and dividend equivalent rights, all at a reported price of $0.0000 per share.